Kura Sushi USA KRUS 深 滬
等待開盤 11-26 09:30:00 美东时间
47.27
+2.780
+6.25%
華盛通- 最 高47.445
- 今 開44.68
- 成交量 25.08万股
- 最 低 44.63
- 昨 收 44.49
- 總市值 5.72亿
- 52周最高 108.46
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 40.03
- 委 比 62.60%
- 總股本 1209.39万
- 歷史最高 122.81
- 量 比 0.83
- 振 幅 6.33%
- 歷史最低 5.07
- 每 手 1
- 風險率 15.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Kura Sushi USA shares are trading higher after reporting better-than-expected Q4 financial results and raising FY 2025 sales guidance.
Kura Sushi USA shares are trading higher after reporting better-than-expected Q...
11-07 06:19
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
A Peek at Kura Sushi USA's Future Earnings
Kura Sushi USA (NASDAQ:KRUS) is gearing up to announce its quarterly earnings o...
11-06 03:01
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
Barclays Maintains Equal-Weight on Kura Sushi USA, Lowers Price Target to $67
Barclays analyst Jeffrey Bernstein maintains Kura Sushi USA (NASDAQ:KRUS) with a Equal-Weight and lowers the price target from $75 to $67.
10-23 00:31
Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital
Keros Therapeutics has repurchased all shares held by ADAR1 Capital Management and Pontifax Venture Capital for approximately $181 million at $17.75 per share, with transactions closing on October 15, 2025. The company also plans to distribute 25% of net cash proceeds from its Takeda license agreement to shareholders and intends to commence a tender offer to repurchase up to $194 million of additional shares at the same price, subject to market c...
10-15 10:30
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
Keros Therapeutics has initiated dosing of the first patient in its Phase 3 RENEW trial for elritercept in adults with transfusion-dependent anemia linked to MDS, triggering a $10 million milestone payment from Takeda under their global license agreement. Elritercept, a TGF-β receptor engineered ligand trap, aims to reduce red blood cell transfusions in these patients.
07-17 12:00
